Leave a Message
Articles

ADHD in Children: Common Questions and Answers

Jennifer G. Chang, Francesca M. Cimino, Weyinshet Gossa

Attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental condition in U.S. children and affects 8.4% of children between two and 17 years of age. Only 62% are treated with medication, less than one-half receive behavior treatment, and nearly one...

Oral Manifestations of Commonly Prescribed Drugs

Aaron Glick, Vinu Sista, Cleverick Johnson

Many adverse drug events present intra- or periorally in isolation or as a clinical symptom of a systemic effect. Clinical recognition and treatment of adverse drug events are important to increase patient compliance, to manage drug therapy, or to detect early signs of...

Editorials

Evidence to Avoid Overtesting and Overuse in Diabetes Mellitus and Other Diseases

Kathleen Barry, David C. Slawson, Allen F. Shaughnessy

Overuse is the use of medical interventions for which the potential harms exceed the potential benefits; this is in contrast to care that is truly necessary, supported by evidence, and likely to provide a net benefit to the patient.1 Various initiatives attempt to help...

AFP Clinical Answers Putting Prevention Into Practice Photo Quiz

Recurrent Facial Rash

Jason Ramirez

A healthy 34-year-old patient presented with a worsening facial rash that first appeared about two years earlier. The rash was initially painless but developed a moderately intense burning sensation with repeated flare-ups. There was no scarring or pruritus.

STEPS

Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus

Afi Mansa Semenya, Stephen A. Wilson

Oral semaglutide (Rybelsus) is a glucagon-like peptide-1 (GLP-1) receptor agonist labeled as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It reduces hyperglycemia by increasing insulin secretion and decreasing glucagon...

Practice Guidelines U.S. Preventive Services Task Force POEMs Information from Your Family Doctor

Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (or NAFLD for short) is a buildup of fat in the liver that is not caused by drinking alcohol. It is the most common liver disease in the United States.



Disclosure

All editors in a position to control content for this activity, AFP journal, are required to disclose any relevant financial relationships. View disclosures.


Tag Legend

Legend

CME Continuing Medical Education Credit
POC Point-of-Care Resource
FREE Free Access
Alg Algorithm
DDx Differential Diagnosis
PtEd Patient Education